MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.23% | 42.92% | -910.31% | 78.13% | 39.37% |
| Total Depreciation and Amortization | -6.82% | 0.69% | 2.26% | -26.12% | 5.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.02% | -37.13% | -7.32% | 146.82% | -198.38% |
| Change in Net Operating Assets | 24.75% | 405.95% | 108.31% | -503.58% | -8.89% |
| Cash from Operations | 372.01% | 94.27% | 4.64% | -175.35% | -57.03% |
| Capital Expenditure | 100.00% | 61.84% | -3.75% | 6.69% | -29.75% |
| Sale of Property, Plant, and Equipment | -100.00% | -88.76% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -89.03% | 10,467.92% | 6.69% | -29.75% |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.00% |
| Total Debt Repaid | -85.83% | -42.86% | 68.30% | 21.36% | 85.30% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.89% | 51.61% | -44.64% | -29.11% | 295.00% |
| Cash from Financing | -147.74% | -116.40% | 321.91% | 16.47% | 89.30% |
| Foreign Exchange rate Adjustments | -388.64% | -116.00% | 147.75% | 133.04% | -354.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.24% | -88.38% | 161.31% | -125.90% | 52.88% |